PA5-31837

antibody from Invitrogen Antibodies

Targeting: PSD4 EFA6B, TIC

Provider product page for PA5-31837

Western blot

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [1]
Comments [0]
Validations
Other assay [2]

Submit

Product number: PA5-31837 - Provider product page
Provider: Invitrogen Antibodies
Product name: PSD4 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Recombinant protein fragment
Description: Recommended positive controls: A431. Predicted reactivity: Mouse (89%), Rat (89%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 1 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

PSD4 protein structure - PA5-31837 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3. KRAS* induces SDC1 membrane recycling through MAPK-PSD4-ARF6 axis. a-d , iKras p53 L/+ PDAC cells were grown in presence (ON) or absence (OFF) of doxycycline for 48 hours or indicated times. REON: cells were grown in absence of doxycycline for 48 hours followed by doxycycline treatment for 24 hours. Treatment of ON or REON samples with trametinib (50 nM), AZD8330 (100 nM), or BKM120 (100 nM) for 16-18 hours is indicated. ( a ) Surface Sdc1 was measured via FACS. ( b ) Cells were detached with trypsin to remove Sdc1 ectodomain and re-suspended in culture medium. (Top) Surface Sdc1 was labeled with anti-Sdc1 antibody at indicated times following re-suspension and measured via FACS. (Bottom) Mean Sdc1 levels. ( c ) Cells grown in presence (ON) or absence (OFF) of doxycycline for 48 hours were subjected to IF staining for Sdc1 (red), Arf6 (green) and DAPI (blue) (scale bar: 20 mum). ( d ) Cell lysates were immunoblotted for Psd4, phosphor-Akt, phosphor-Erk, Kras and ss-Actin. a-d: Data are representative of two independent experiments with similar results.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Extended Data Figure 7. MAPK-PSD4-ARF6 axis mediates KRAS*-dependent SDC1 membrane localization. a , Cells were grown in presence (ON) or absence (OFF) of doxycycline or treated with AZD8330 (100 nM) for 16-18 hours. (Top) ARF6 activity was measured with GGA3-PBD pull down assay. GTP and GDP used as positive and negative controls, respectively. (Bottom insert) ARF6 activity was calculated as ratio of captured Arf6:input Arf6/vinculin. b , iKras p53 L/+ tumor cells were grown in the presence (ON) or absence (OFF) of doxycycline, or treated with AZD8330 (100 nM) for 16-18 hours. Cell lysates were used for measurement of PIPK activity (n=3 biological replicates; Data are mean + s.d.). P -values were determined by unpaired two-sided Student's t -test. c , Representative images of morphology change in iKras p53 L/+ tumor cells with dominant negative Arf6 (Arf T27N ) or constitutively active Arf6 (Arf Q67L ). Experiments were repeated 3 times with similar results. d , iKras p53 L/+ tumor cells stably expressing Arf6 Q67L or its empty vector (Vec) were grown in the presence (ON) or absence (OFF) of doxycycline for 48 hours and surface Sdc1 were measured with FACS using anti-Sdc1 antibody (Top). The fluorescence intensity of surface SDC1 is shown (Bottom) (n=4 biological replicates; Data are mean + s.d.). P -values were determined by paired two-sided Student's t -test. e , iKras p53 L/+ tumor cells stably expressing Arf6 T27N or empty vector (Vec) were grown in the presence (ON) or a